Novartis Ag (NVS) 84.67 $NVS
Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 1:05PM CDT
Here at The Motley Fool we spend a lot of time dissecting companies at the leading edge of the largest investment opportunities. Being a specialist in the Health Care sector, that means I devote a lot of my research to drugs aimed at treating some of...
Iris Biotechnologies Receives 2014 IAIR Award - Best Company for Leadership in Personalized Medicine in North America
Marketwire - Fri Apr 18, 2:38PM CDT
Iris Biotechnologies Inc. (OTCQB: IRSB) is a winner of the 2014 IAIR AWARDS, which took place in New York on Tuesday, April 15, 2014, at the Yale Club in Manhattan. (www.iairawards.com). Previous winners include Novartis, IBM, Apple, Microsoft, Samsung and Bank of China.
Roche Meets Sales Estimates in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:00PM CDT
Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.
Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...
Global Hormone-Sensitive Prostate Cancer Global Clinical Trials Review 2014 - Profiles of 16 Top Organisations
M2 - Thu Apr 17, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m7lf5/hormonesensitive) has announced the addition of the "Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014 provides data on the Hormone-Sensitive Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone-Sensitive Prostate Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies/Organisations Participating in Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials - Novartis AG - Ferring International Center S.A. - Johnson & Johnson - GlaxoSmithKline plc - Dendreon Corporation - CMX Research Inc. - National Cancer Institute - Massachusetts General Hospital - University of California, San Francisco - Azienda Provinciale per i Servizi Sanitari - Comprehensive Cancer Centers of Nevada - City of Hope National Medical Center - Oslo University Hospital - Keio University - Barbara Ann Karmanos Cancer Institute - University of Pennsylvania For more information visit http://www.researchandmarkets.com/research/9m...esensitive
Global Malignant Mesothelioma Clinical Trials Review 2014 - Profiles of 10 Companies & 9 Organisations
M2 - Thu Apr 17, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/llpnwn/malignant) has announced the addition of the "Malignant Mesothelioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Mesothelioma Global Clinical Trials Review, H1, 2014 provides data on the Malignant Mesothelioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Mesothelioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Mesothelioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Eli Lilly and Company - Novartis AG - Verastem, Inc. - Merck & Co., Inc. - AstraZeneca PLC - Polaris Group - MolMed S.p.A. - Eisai Inc. - Aduro BioTech, Inc. - Anza Therapeutics, Inc. - National Cancer Institute - Memorial Sloan Kettering Cancer Center - European Organization for Research and Treatment of Cancer - The University of Texas M. D. Anderson Cancer Center - Columbia University - Istituto Clinico Humanitas - Fox Chase Cancer Center - Stanford University - University Health Network For more information visit http://www.researchandmarkets.com/research/llpnwn/malignant
Foreign Stocks: Balance Your Portfolio and Profit From Global Growth
Selena Maranjian, The Motley Fool - Motley Fool - Wed Apr 16, 4:32PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some foreign stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Vanguard FTSE All-World Ex-US ETF ...
Global Meningioma Clinical Trials Review 2014
M2 - Wed Apr 16, 10:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xnw5zr/meningioma_global) has announced the addition of the "Meningioma Global Clinical Trials Review, H1, 2014" report to their offering. Meningioma Global Clinical Trials Review, H1, 2014 provides data on the Meningioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Meningioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Meningioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies - Novartis AG - Pacira Pharmaceuticals, Inc. - Mundipharma International Limited - China Nuokang Bio-Pharmaceutical Inc. - Burzynski Research Institute, Inc. - Arno Therapeutics, Inc. Organisations - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Northwestern University - Memorial Sloan Kettering Cancer Center - The University of Utah - Abramson Cancer Center - European Organization for Research and Treatment of Cancer - Southwest Oncology Group - City of Hope National Medical Center - New York University School of Medicine For more information visit http://www.researchandmarkets.com/research/xn...oma_global
Proteus Digital Health Grows Leadership Team and Board of Directors with Former Executives from Novartis, Microsoft and Egreetings Network
Business Wire - Wed Apr 16, 10:00AM CDT
Proteus Digital Health(TM), a leading digital medicines company, today announced the expansion of the company's executive team and board of directors with the addition of three industry leaders across consumer technology and global pharmaceuticals.
Research and Markets: Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
Business Wire - Wed Apr 16, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xrdnxd/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
Research and Markets: Latin America OTC Pharmaceuticals Market 2014-2018 With Bayer HealthCare AG., EMS S.A., Hypermarcas S.A., and Novartis AG Dominating
Business Wire - Wed Apr 16, 4:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zjf2h4/otc) has announced the addition of the "OTC Pharmaceuticals Market in Latin America 2014-2018" report to their offering.
Latin America OTC Pharmaceuticals Market 2014-2018 with Bayer HealthCare AG., EMS S.A., Hypermarcas S.A., and Novartis AG Dominating
M2 - Wed Apr 16, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3ggp7m/otc) has announced the addition of the "OTC Pharmaceuticals Market in Latin America 2014-2018" report to their offering. The OTC Pharmaceuticals Market in Latin America market to grow at a CAGR of 14% to 2018 One of the major drivers is the increasing switch from prescription to OTC drugs, which increases the number of OTC drugs available. The development and manufacture of drugs is a complex and time-consuming process, and it requires huge financial investments. As many vendors are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Certain vendors outsource different parts of the R&D process (such as product characterization testing and toxicology testing) to contract research organizations. Similarly, certain vendors are outsourcing part of their manufacturing process, or even the entire manufacturing process, to various organizations. Thus, outsourcing is one of the main trends in this market at present. Further, the report states that one of the major challenges in the market is the stringent regulations posed by regulatory bodies such as Ag?ncia Nacional de Vigil?ncia Sanit?ria, Brazil. Product recalls negatively affect a company's image, resulting in customers opting for other products available in the market, which leads to a fall in sales. Key vendors dominating this space include: - Bayer HealthCare AG. - EMS S.A. - Hypermarcas S.A. - Novartis AG. Other vendors mentioned in the report are: - Boehringer Ingelheim GmbH. - Genomma Lab Internacional SAB. - GlaxoSmithKline plc - Johnson & Johnson - Pfizer Inc - Takeda Pharmaceutical Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3ggp7m/otc
Does Pfizer Offer Good Value?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 15, 1:30PM CDT
Over the past 12 months, Pfizer has underperformed the S&P 500 by a wide margin. The company is just 4.6% ahead of the benchmark over the past five years. Following the recent industry-wide sell-off, it crossed into what looks like deep value...
Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Forest Laboratories Inc. (NYSE: FRX), Novatis AG (NYSE: NVS) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1162-100free.
Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55stl2/postpolycythemia) has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development - AstraZeneca PLC - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Incyte Corporation - Pharma Mar, S.A. Drug Profiles - pacritinib - momelotinib - panobinostat - plitidepsin - luminespib - simtuzumab - INCB-39110 - AZD-1480 - NS-018 - buparlisib hydrochloride For more information visit http://www.researchandmarkets.com/research/55...lycythemia
Global Fracture Therapeutic Pipeline Review Report 2014
M2 - Tue Apr 15, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rcn4c9/fracture) has announced the addition of the "Fracture - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fracture and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Fracture - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fracture and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fracture pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Fracture - Companies Involved in Therapeutics Development - Eli Lilly and Company - Kuros Biosurgery AG - Novartis AG - Kolon Life Science, Inc. - TissueGene, Inc. - Radius Health, Inc. - Arcarios BV - Escape Therapeutics, Inc. - Orbsen Therapeutics Limited - OrgaNext Research BV Drug Profiles - teriparatide - BA-058 - KUR-113 - bimagrumab - (nandrolone decanoate cholecalciferol) - rusalatide acetate - KLS-Bfr - OsteoStem - TG-B - Stromal Cell Therapy For Fracture Repair - Bone Morphogenetic Protein Modulators - Epoxyeicosatreienoic Acid Analogues for Musculoskeletal Disorders - Drugs to Modulate PPAR-Delta for Musculoskeletal Disorders - Hydroxyprostaglandin E2 Analogues for Musculoskeletal Disorders For more information visit http://www.researchandmarkets.com/research/rcn4c9/fracture
Global Food Allergy Therapeutic Pipeline Report 2014
M2 - Tue Apr 15, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r8sxtn/food_allergy) has announced the addition of the "Food Allergy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Food Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Food Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Food Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Food Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Food Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Food Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Food Allergy - Companies Involved in Therapeutics Development - Novartis AG - Selecta Biosciences, Inc. - Biomay AG - Tunitas Therapeutics, Inc. Drug Profiles - QGE-031 - Fish Hypoallergenic Vaccine - Epsi-Gam - Pru p 3.02 - Pru p 3.03 - Allergen Vaccine Program - Vaccine For Food Allergy For more information visit http://www.researchandmarkets.com/research/r8...od_allergy
Global Mycobacterium Tuberculosis Infections Pipeline Review
M2 - Tue Apr 15, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3zqhd/mycobacterium) has announced the addition of the "Mycobacterium Tuberculosis Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mycobacterium Tuberculosis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycobacterium Tuberculosis Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Mycobacterium Tuberculosis Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Mycobacterium Tuberculosis Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Mycobacterium Tuberculosis Infections - Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Novartis AG - Oragenics, Inc. - Debiopharm International S.A. - Archivel Farma S.L. - Sphaera Pharma Pvt. Ltd. - Bioversys AG Drug Profiles - RUTI Vaccine - MU-1140 - MU-1140-S - (BV-6481 ethionamide) - Biotin Triazoles - Mycobacterial Gyrase Inhibitor Program - rAMtb-SIVgag Vaccine - HT-04 - NITD-349 - Small Molecules to Inhibit Structural Protein FtsZ for Bacterial Infections - Small Molecules for Bacterial and Viral Infections - Fabl Inhibitor Program - Aminopyrazinamides - MDR And XDR Tuberculosis Program - Small Molecules for Bacterial Infections - KKL-35 - R-12 - R-13 - Compound-87 - NC-00094221 - Cephalosporins For more information visit http://www.researchandmarkets.com/research/l3...obacterium
Global Meningococcemia (Meningococcal Infections) Pipeline Review 2014
M2 - Tue Apr 15, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mrlmlf/meningococcemia) has announced the addition of the "Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Meningococcemia (Meningococcal Infections), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Meningococcemia (Meningococcal Infections) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Meningococcemia (Meningococcal Infections) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Meningococcemia (Meningococcal Infections) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Meningococcemia (Meningococcal Infections) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Meningococcemia (Meningococcal Infections) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Meningococcemia (Meningococcal Infections) - Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Biological E. Limited - Novartis AG - Panacea Biotec Limited - Wellstat Vaccines, LLC - Beijing Minhai Biotechnology Co., Ltd - Chongqing Zhifei Biological Products Co., Ltd. - Sanofi Pasteur SA Drug Profiles - Meninge ACYW Conjugate - Nimenrix - Meningococcal ACW135 Vaccine (Plain) - Meningococcal ACYW135 Vaccine (Plain) - Meningococcal ACYW135X Vaccine (Plain) - MenABCWY Conjugate Vaccine - Meningitis Vaccine - Meningococcus CY Polysaccharide Conjugate Vaccine - Meningococcal B Vaccine - ABC Meningococcal Vaccine - Meningococcus B Vaccine - Meningococcal Vaccine - Meningococcal Conjugate Vaccine For more information visit http://www.researchandmarkets.com/research/mr...gococcemia
Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 1:05PM CDT
Here at The Motley Fool we spend a lot of time dissecting companies at the leading edge of the largest investment opportunities. Being a specialist in the Health Care sector, that means I devote a lot of my research to drugs aimed at treating some of...
Iris Biotechnologies Receives 2014 IAIR Award - Best Company for Leadership in Personalized Medicine in North America
Marketwire - Fri Apr 18, 2:38PM CDT
Iris Biotechnologies Inc. (OTCQB: IRSB) is a winner of the 2014 IAIR AWARDS, which took place in New York on Tuesday, April 15, 2014, at the Yale Club in Manhattan. (www.iairawards.com). Previous winners include Novartis, IBM, Apple, Microsoft, Samsung and Bank of China.
Roche Meets Sales Estimates in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:00PM CDT
Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.
Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...
Global Hormone-Sensitive Prostate Cancer Global Clinical Trials Review 2014 - Profiles of 16 Top Organisations
M2 - Thu Apr 17, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m7lf5/hormonesensitive) has announced the addition of the "Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014 provides data on the Hormone-Sensitive Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone-Sensitive Prostate Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies/Organisations Participating in Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials - Novartis AG - Ferring International Center S.A. - Johnson & Johnson - GlaxoSmithKline plc - Dendreon Corporation - CMX Research Inc. - National Cancer Institute - Massachusetts General Hospital - University of California, San Francisco - Azienda Provinciale per i Servizi Sanitari - Comprehensive Cancer Centers of Nevada - City of Hope National Medical Center - Oslo University Hospital - Keio University - Barbara Ann Karmanos Cancer Institute - University of Pennsylvania For more information visit http://www.researchandmarkets.com/research/9m...esensitive
Global Malignant Mesothelioma Clinical Trials Review 2014 - Profiles of 10 Companies & 9 Organisations
M2 - Thu Apr 17, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/llpnwn/malignant) has announced the addition of the "Malignant Mesothelioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Mesothelioma Global Clinical Trials Review, H1, 2014 provides data on the Malignant Mesothelioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Mesothelioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Mesothelioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Eli Lilly and Company - Novartis AG - Verastem, Inc. - Merck & Co., Inc. - AstraZeneca PLC - Polaris Group - MolMed S.p.A. - Eisai Inc. - Aduro BioTech, Inc. - Anza Therapeutics, Inc. - National Cancer Institute - Memorial Sloan Kettering Cancer Center - European Organization for Research and Treatment of Cancer - The University of Texas M. D. Anderson Cancer Center - Columbia University - Istituto Clinico Humanitas - Fox Chase Cancer Center - Stanford University - University Health Network For more information visit http://www.researchandmarkets.com/research/llpnwn/malignant
Foreign Stocks: Balance Your Portfolio and Profit From Global Growth
Selena Maranjian, The Motley Fool - Motley Fool - Wed Apr 16, 4:32PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some foreign stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Vanguard FTSE All-World Ex-US ETF ...
Global Meningioma Clinical Trials Review 2014
M2 - Wed Apr 16, 10:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xnw5zr/meningioma_global) has announced the addition of the "Meningioma Global Clinical Trials Review, H1, 2014" report to their offering. Meningioma Global Clinical Trials Review, H1, 2014 provides data on the Meningioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Meningioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Meningioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies - Novartis AG - Pacira Pharmaceuticals, Inc. - Mundipharma International Limited - China Nuokang Bio-Pharmaceutical Inc. - Burzynski Research Institute, Inc. - Arno Therapeutics, Inc. Organisations - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Northwestern University - Memorial Sloan Kettering Cancer Center - The University of Utah - Abramson Cancer Center - European Organization for Research and Treatment of Cancer - Southwest Oncology Group - City of Hope National Medical Center - New York University School of Medicine For more information visit http://www.researchandmarkets.com/research/xn...oma_global
Proteus Digital Health Grows Leadership Team and Board of Directors with Former Executives from Novartis, Microsoft and Egreetings Network
Business Wire - Wed Apr 16, 10:00AM CDT
Proteus Digital Health(TM), a leading digital medicines company, today announced the expansion of the company's executive team and board of directors with the addition of three industry leaders across consumer technology and global pharmaceuticals.
Research and Markets: Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
Business Wire - Wed Apr 16, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xrdnxd/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
Research and Markets: Latin America OTC Pharmaceuticals Market 2014-2018 With Bayer HealthCare AG., EMS S.A., Hypermarcas S.A., and Novartis AG Dominating
Business Wire - Wed Apr 16, 4:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zjf2h4/otc) has announced the addition of the "OTC Pharmaceuticals Market in Latin America 2014-2018" report to their offering.
Latin America OTC Pharmaceuticals Market 2014-2018 with Bayer HealthCare AG., EMS S.A., Hypermarcas S.A., and Novartis AG Dominating
M2 - Wed Apr 16, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3ggp7m/otc) has announced the addition of the "OTC Pharmaceuticals Market in Latin America 2014-2018" report to their offering. The OTC Pharmaceuticals Market in Latin America market to grow at a CAGR of 14% to 2018 One of the major drivers is the increasing switch from prescription to OTC drugs, which increases the number of OTC drugs available. The development and manufacture of drugs is a complex and time-consuming process, and it requires huge financial investments. As many vendors are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Certain vendors outsource different parts of the R&D process (such as product characterization testing and toxicology testing) to contract research organizations. Similarly, certain vendors are outsourcing part of their manufacturing process, or even the entire manufacturing process, to various organizations. Thus, outsourcing is one of the main trends in this market at present. Further, the report states that one of the major challenges in the market is the stringent regulations posed by regulatory bodies such as Ag?ncia Nacional de Vigil?ncia Sanit?ria, Brazil. Product recalls negatively affect a company's image, resulting in customers opting for other products available in the market, which leads to a fall in sales. Key vendors dominating this space include: - Bayer HealthCare AG. - EMS S.A. - Hypermarcas S.A. - Novartis AG. Other vendors mentioned in the report are: - Boehringer Ingelheim GmbH. - Genomma Lab Internacional SAB. - GlaxoSmithKline plc - Johnson & Johnson - Pfizer Inc - Takeda Pharmaceutical Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3ggp7m/otc
Does Pfizer Offer Good Value?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 15, 1:30PM CDT
Over the past 12 months, Pfizer has underperformed the S&P 500 by a wide margin. The company is just 4.6% ahead of the benchmark over the past five years. Following the recent industry-wide sell-off, it crossed into what looks like deep value...
Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Forest Laboratories Inc. (NYSE: FRX), Novatis AG (NYSE: NVS) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1162-100free.
Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55stl2/postpolycythemia) has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development - AstraZeneca PLC - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Incyte Corporation - Pharma Mar, S.A. Drug Profiles - pacritinib - momelotinib - panobinostat - plitidepsin - luminespib - simtuzumab - INCB-39110 - AZD-1480 - NS-018 - buparlisib hydrochloride For more information visit http://www.researchandmarkets.com/research/55...lycythemia
Global Fracture Therapeutic Pipeline Review Report 2014
M2 - Tue Apr 15, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rcn4c9/fracture) has announced the addition of the "Fracture - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fracture and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Fracture - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fracture and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fracture pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Fracture - Companies Involved in Therapeutics Development - Eli Lilly and Company - Kuros Biosurgery AG - Novartis AG - Kolon Life Science, Inc. - TissueGene, Inc. - Radius Health, Inc. - Arcarios BV - Escape Therapeutics, Inc. - Orbsen Therapeutics Limited - OrgaNext Research BV Drug Profiles - teriparatide - BA-058 - KUR-113 - bimagrumab - (nandrolone decanoate cholecalciferol) - rusalatide acetate - KLS-Bfr - OsteoStem - TG-B - Stromal Cell Therapy For Fracture Repair - Bone Morphogenetic Protein Modulators - Epoxyeicosatreienoic Acid Analogues for Musculoskeletal Disorders - Drugs to Modulate PPAR-Delta for Musculoskeletal Disorders - Hydroxyprostaglandin E2 Analogues for Musculoskeletal Disorders For more information visit http://www.researchandmarkets.com/research/rcn4c9/fracture
Global Food Allergy Therapeutic Pipeline Report 2014
M2 - Tue Apr 15, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r8sxtn/food_allergy) has announced the addition of the "Food Allergy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Food Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Food Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Food Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Food Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Food Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Food Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Food Allergy - Companies Involved in Therapeutics Development - Novartis AG - Selecta Biosciences, Inc. - Biomay AG - Tunitas Therapeutics, Inc. Drug Profiles - QGE-031 - Fish Hypoallergenic Vaccine - Epsi-Gam - Pru p 3.02 - Pru p 3.03 - Allergen Vaccine Program - Vaccine For Food Allergy For more information visit http://www.researchandmarkets.com/research/r8...od_allergy
Global Mycobacterium Tuberculosis Infections Pipeline Review
M2 - Tue Apr 15, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3zqhd/mycobacterium) has announced the addition of the "Mycobacterium Tuberculosis Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mycobacterium Tuberculosis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycobacterium Tuberculosis Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Mycobacterium Tuberculosis Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Mycobacterium Tuberculosis Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Mycobacterium Tuberculosis Infections - Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Novartis AG - Oragenics, Inc. - Debiopharm International S.A. - Archivel Farma S.L. - Sphaera Pharma Pvt. Ltd. - Bioversys AG Drug Profiles - RUTI Vaccine - MU-1140 - MU-1140-S - (BV-6481 ethionamide) - Biotin Triazoles - Mycobacterial Gyrase Inhibitor Program - rAMtb-SIVgag Vaccine - HT-04 - NITD-349 - Small Molecules to Inhibit Structural Protein FtsZ for Bacterial Infections - Small Molecules for Bacterial and Viral Infections - Fabl Inhibitor Program - Aminopyrazinamides - MDR And XDR Tuberculosis Program - Small Molecules for Bacterial Infections - KKL-35 - R-12 - R-13 - Compound-87 - NC-00094221 - Cephalosporins For more information visit http://www.researchandmarkets.com/research/l3...obacterium
Global Meningococcemia (Meningococcal Infections) Pipeline Review 2014
M2 - Tue Apr 15, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mrlmlf/meningococcemia) has announced the addition of the "Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Meningococcemia (Meningococcal Infections), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Meningococcemia (Meningococcal Infections) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Meningococcemia (Meningococcal Infections) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Meningococcemia (Meningococcal Infections) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Meningococcemia (Meningococcal Infections) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Meningococcemia (Meningococcal Infections) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Meningococcemia (Meningococcal Infections) - Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Biological E. Limited - Novartis AG - Panacea Biotec Limited - Wellstat Vaccines, LLC - Beijing Minhai Biotechnology Co., Ltd - Chongqing Zhifei Biological Products Co., Ltd. - Sanofi Pasteur SA Drug Profiles - Meninge ACYW Conjugate - Nimenrix - Meningococcal ACW135 Vaccine (Plain) - Meningococcal ACYW135 Vaccine (Plain) - Meningococcal ACYW135X Vaccine (Plain) - MenABCWY Conjugate Vaccine - Meningitis Vaccine - Meningococcus CY Polysaccharide Conjugate Vaccine - Meningococcal B Vaccine - ABC Meningococcal Vaccine - Meningococcus B Vaccine - Meningococcal Vaccine - Meningococcal Conjugate Vaccine For more information visit http://www.researchandmarkets.com/research/mr...gococcemia
